BioLife Sciences Inc. (OTC: BLFE) Announces Letter of Intent for Exclusive Licensing Deal with Canadian Firm
February 02 2023 - 8:32AM
InvestorsHub NewsWire
HENDERSON, NV -- February 2, 2023 -- InvestorsHub NewsWire
-- BioLife Sciences (OTCPK:
BLFE) is pleased to announce that it has entered into a
non-binding letter of intent (“LOI”) dated
February 01, 2023 with Canadian Company–Work In Motion pursuant to
which the parties will complete an exclusive licensing agreement
for the development and commercialization of custom designed copper
infused bamboo gardening gloves.
Transaction
The final structure of the Transaction will be determined by the
parties following corporate and securities law advice. The
Transaction is an arm’s length transaction and pursuant to the
terms of the LOI the parties intend to sign a definitive agreement
(the “Definitive Agreement”) in respect of the Transaction; BioLife
Sciences is intended to assume sole responsibility for the
development and commercialization of private label copper infused
bamboo gardening gloves.
Completion of the Transaction is subject to a number of
conditions, including but not limited to the following key
conditions:
- execution of the Definitive Agreement.
- completion of mutually satisfactory due diligence; and
- successful sourcing of required equipment and design
specifications.
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products
from the lab or small-scale production into wider market adoption.
Its core business develops, licenses and distributes antimicrobial
products and disruptive technology. One of BioLife Sciences’ core
building block strategies is to develop, partner and assist
innovative companies with the commercialization of leading-edge
technologies.
About Work In Motion
Work In Motion is a leading products distributor, headquartered
in Canada working in alliance with industry leading manufacturers
sourcing multidisciplinary products connecting international
distribution chains alongside custom product development and
private label services.
Disclaimer
The information in this news release includes certain
information and statements about management's view of future
events, expectations, plans and prospects that constitute forward
looking statements. These statements are based upon assumptions
that are subject to significant risks and uncertainties. Because of
these risks and uncertainties and as a result of a variety of
factors, the actual results, expectations, achievements or
performance may differ materially from those anticipated and
indicated by these forward-looking statements. Forward-looking
statements in this news release include, but are not limited to,
the ability of the Corporation to complete a qualifying
transaction. Any number of factors could cause actual results to
differ materially from these forward-looking statements as well as
future results. Although the Corporation believes that the
expectations reflected in forward looking statements are
reasonable, it can give no assurance that the expectations of any
forward-looking statements will prove to be correct. Except as
required by law, the Corporation disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Contact Information:
www.biolifesciences.com
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
BioLife Sciences (CE) (USOTC:BLFE)
Historical Stock Chart
From Feb 2025 to Mar 2025
BioLife Sciences (CE) (USOTC:BLFE)
Historical Stock Chart
From Mar 2024 to Mar 2025